共 406 条
[31]
Kim JW(2015)Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors Expert Opin Biol Ther 15 1799-1235
[32]
Choi YJ(2013)Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF) BMC Cancer 13 11-1143
[33]
Park IH(2016)Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review J Oncol Pharm Pract 22 702-1184
[34]
Lee KS(2010)Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide Eur J Cancer Care (Engl) 19 200-2801
[35]
Seo JH(2008)Pegfilgrastim; a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy Expert Opin Biol Ther 8 993-647
[36]
Shin SW(2003)Impact of long-acting growth factors on practice dynamics and patient satisfaction Pharmacotherapy 23 101S-321
[37]
Kim YH(2018)A multicenter, randomized, controlled, phase IV clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer Natl Med J China 98 1231-undefined
[38]
Kim JS(2015)Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy Support Care Cancer 23 1137-undefined
[39]
Park KH(2005)First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 1178-undefined
[40]
Marsh JC(2018)Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects Brit J Clin Pharmacol 84 2790-undefined